{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:43:49Z","timestamp":1790837029626,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmdjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jmoldx.2019.12.003","type":"journal-article","created":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T16:55:21Z","timestamp":1577206521000},"page":"396-404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Apparently Heterozygous TP53 Pathogenic Variants May Be Blood Limited in Patients Undergoing Hereditary Cancer Panel Testing"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9374-3185","authenticated-orcid":false,"given":"Jessica L.","family":"Mester","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Postula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1652-6336","authenticated-orcid":false,"given":"Amy","family":"Stettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6778-2313","authenticated-orcid":false,"given":"Jeffrey","family":"Bissonnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5199-1025","authenticated-orcid":false,"given":"Patricia D.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel T.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8468-2843","authenticated-orcid":false,"given":"Kathleen S.","family":"Hruska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2019.12.003_bib1","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1126\/science.1978757","article-title":"Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms","volume":"250","author":"Malkin","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib2","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1002\/cncr.30248","article-title":"Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort","volume":"122","author":"Mai","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib3","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s10549-012-1993-9","article-title":"Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort","volume":"133","author":"Masciari","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib4","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(16)30249-2","article-title":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study","volume":"17","author":"Villani","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.6004\/jnccn.2017.0003","article-title":"NCCN guidelines insights: genetic\/familial high-risk assessment: breast and ovarian, version 2.2017","volume":"15","author":"Daly","year":"2017","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib6","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ajmg.a.32574","article-title":"Somatic TP53 mutation mosaicism in a patient with Li-Fraumeni syndrome","volume":"149A","author":"Prochazkova","year":"2009","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib7","doi-asserted-by":"crossref","first-page":"e96531","DOI":"10.1371\/journal.pone.0096531","article-title":"A pathogenic mosaic TP53 mutation in two germ layers detected by next generation sequencing","volume":"9","author":"Behjati","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cancergen.2017.07.001","article-title":"Constitutional mosaicism of a de novo TP53 mutation in a patient with bilateral choroid plexus carcinoma","volume":"216\u2013217","author":"Trubicka","year":"2017","journal-title":"Cancer Genet"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/jmedgenet-2017-104976","article-title":"Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome","volume":"55","author":"Renaux-Petel","year":"2018","journal-title":"J Med Genet"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/humu.10190","article-title":"TP53 in hematological cancer: low incidence of mutations with significant clinical relevance","volume":"21","author":"Peller","year":"2003","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamaoncol.2015.6053","article-title":"Somatic mosaic mutations in PPM1D and TP53 in the blood of women with ovarian carcinoma","volume":"2","author":"Swisher","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib12","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib13","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1470-2045(16)30627-1","article-title":"Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study","volume":"18","author":"Gillis","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib14","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib15","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib16","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/bjc.1994.76","article-title":"The 1993 Walter Hubert lecture: the role of the p53 tumour-suppressor gene in tumorigenesis","volume":"69","author":"Levine","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nrc1455","article-title":"Post-translational modification of p53 in tumorigenesis","volume":"4","author":"Bode","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib19","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0140-6736(03)12856-5","article-title":"Prediction of pathogenic mutations in patients with early-onset breast cancer by family history","volume":"361","author":"Lalloo","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.cancergen.2017.01.002","article-title":"Detection of somatic variants in peripheral blood lymphocytes using a next generation sequencing multigene pan cancer panel","volume":"211","author":"Coffee","year":"2017","journal-title":"Cancer Genet"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.6004\/jnccn.2017.7058","article-title":"Misdiagnosis of Li-Fraumeni syndrome in a patient with clonal hematopoiesis and a somatic TP53 mutation","volume":"16","author":"Mitchell","year":"2018","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/humu.23910","article-title":"A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically","volume":"41","author":"Coffee","year":"2020","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib23","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/gim.2017.196","article-title":"Somatic TP53 variants frequently confound germ-line testing results","volume":"20","author":"Weitzel","year":"2018","journal-title":"Genet Med"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib24","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/gim.2017.254","article-title":"MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer","volume":"20","author":"Roberts","year":"2018","journal-title":"Genet Med"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib26","first-page":"5358","article-title":"A cancer family syndrome in twenty-four kindreds","volume":"48","author":"Li","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib27","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1200\/JCO.2009.22.7967","article-title":"2009 Version of the Chompret criteria for Li Fraumeni syndrome","volume":"27","author":"Tinat","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib28","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","article-title":"Revisiting Li-Fraumeni syndrome from TP53 mutation carriers","volume":"33","author":"Bougeard","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib29","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/humu.23653","article-title":"Diagnosis of Li-Fraumeni syndrome: differentiating TP53 germline mutations from clonal hematopoiesis: results of the observational AGO-TR1 trial","volume":"31","author":"Weber-Lassalle","year":"2018","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/jmg.2009.073429","article-title":"TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes","volume":"47","author":"Ruijs","year":"2010","journal-title":"J Med Genet"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib31","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1200\/JCO.2008.16.6959","article-title":"Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations","volume":"27","author":"Gonzalez","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib32","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/cncr.26377","article-title":"Early onset HER2-positive breast cancer is associated with germline TP53 mutations","volume":"118","author":"Melhem-Bertrandt","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3816\/CBC.2004.n.011","article-title":"HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues","volume":"5","author":"Owens","year":"2004","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib34","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/humu.20980","article-title":"Parallel sequencing used in detection of mosaic mutations: comparison with four diagnostic DNA screening techniques","volume":"30","author":"Rohlin","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13058-019-1193-1","article-title":"Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis","volume":"21","author":"Batalini","year":"2019","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib36","first-page":"317","article-title":"Clonal hematopoiesis of indeterminate potential","volume":"113","author":"Heuser","year":"2016","journal-title":"Dtsch Arzteblatt Int"},{"key":"10.1016\/j.jmoldx.2019.12.003_bib37","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157819304593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157819304593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:14:21Z","timestamp":1761502461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157819304593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1525157819304593"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2019.12.003","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apparently Heterozygous TP53 Pathogenic Variants May Be Blood Limited in Patients Undergoing Hereditary Cancer Panel Testing","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2019.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}